Clinical trials: Mammary Tumor
High Grade Serous Carcinoma, Triple Negative Breast Cancer
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
The purpose of this Phase I study is to determine if the PARP inhibitor olaparib can be safely combined with navitoclax, an inhibitor of Bcl-2/Bcl-XL, in women with TNBC who have somatic or germline mutations in breast cancer…
- Conditions
- High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer
- Trial name
- NCT05358639
- Testing
- Olaparib tablet, Navitoclax
- Where
- 3 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Sunnybrook Health Sciences Centre
Triple-negative Breast Cancer
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)
This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel…
- Trial name
- CITRINE (NCT04296175)
- Testing
- Epirubicin, CTX, Paclitaxel
- Where
- China
- Volunteers
- 808 people
- Sponsor
- Fudan University
Breast Cancer
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
The Olanzapine Regimen will be superior to the Standard Regimen, as measured by the proportion of patients with Complete Response in the 120 hours following AC chemotherapy.
- Trial name
- NCT03079219
- Testing
- Experimental drug: Aprepitant, Experimental drug: Ondansetron, Experimental drug: Dexamethasone
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- CCTU
Breast Cancer
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
HER2 is a protein that sits on the surface of breast cancer cells in some people. Because you are one of these people, your breast cancer is called "HER2-positive." The HER2 protein is involved in the growth of your breast…
- Trial name
- NCT00721630
- Testing
- capecitabine, lapatinib
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients
The research design is a randomized control trial to evaluate the effectiveness of character strengths-based intervention in enhancing self-esteem, quality of life and alleviating depression in breast cancer patients.
- Trial name
- NCT04219267
- Testing
- character strengths-based intervention, early memories
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Chinese University of Hong Kong
Cancer Prevention
Project MOVE: Increasing Physical Activity Among Breast Cancer Survivors
The purpose of this research is to implement and evaluate the feasibility of Project MOVE, a program aimed to increase physical activity among breast cancer survivors through microgrants and financial incentives.
- Trial name
- NCT03548636
- Testing
- Single-Arm Feasibility Study
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Breast Neoplasms
Robotic-Assisted vs. Endoscopic-Assisted Sentinel Lymph Node Biopsy in Breast Cancer
This is a retrospective observational study comparing the accuracy and safety of robotic-assisted versus endoscopic-assisted sentinel lymph node biopsy (SLNB) in patients with breast cancer.
- Trial name
- NCT07741734
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Breast Cancer, Solid Tumor
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Trial name
- NCT06503783
- Testing
- BL-M17D1
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Estrogen Receptor Negative, HER2/Neu Negative
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase I clinical trial studies the side effects and the best dose of dinaciclib when given together with epirubicin hydrochloride (epirubicin) in patients with metastatic (cancer that has spread to other parts of the body)…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01624441
- Testing
- Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Early Stage Breast Cancer
A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients
Single arm, prospective, multi-center, non-randomized study of subjects treated with single fraction, intra-operative radiation therapy at the time of lumpectomy for early stage breast cancer.To assess the rate of ipsilateral…
- Trial name
- NCT03561454
- Testing
- IORT
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MedStar Franklin Square Medical Center
Metastatic Breast Cancer
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.
- Trial name
- NCT02536339
- Testing
- Pertuzumab, Trastuzumab
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
The goal of this study is to evaluate if adding community services navigation to the standard referral process for social needs is an effective and scalable strategy for addressing disparities in follow-up to abnormal breast…
- Trial name
- B-SINCERE (NCT06305312)
- Testing
- Community Service Navigation, Usual Care
- Where
- United States
- Volunteers
- 1,450 people
- Sponsor
- University of Utah
Breast Cancer
Rapid Histologic Assessment for Stereotactic Breast Biopsy: Enhancing Early Detection With Miniature Mass Spectrometry and AI
Breast cancer is the leading cancer among Taiwanese women, and it is the second leading cause of cancer-related deaths in women.
- Trial name
- NCT06663228
- Testing
- MMS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Pancreatic Cancer, Breast Cancer
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
This project utilizes LRRC15-specific targeted PET radiotracers to perform PET/MR or PET/CT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15…
- Conditions
- Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma
- Trial name
- NCT07552467
- Testing
- Specific PET imaging agents targeting LRRC15
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lymph Node, Breastcancer
CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer
To establish a predicting system on axillary lymph node metastasis based on peripheral blood CK19mRNA and contrast-enhanced ultrasound.
- Trial name
- CK-CEUS (NCT02992067)
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Patients, Therapy Related Tumor
Loreline Study: Characterization of Long Responders Under Eribuline
There is currently no strict recommendations for the management of patients who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy for advanced breast cancer.
- Trial name
- Loreline (NCT03771183)
- Testing
- Patients in long response during Halaven® treatment
- Where
- 5 sites in France
- Volunteers
- 97 people
- Sponsor
- Centre Jean Perrin
Breast Cancer
Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer
Intensive sequential chemotherapy with Adriamycin Taxol and Cytoxan in the treatment of locally advanced breast cancer
- Trial name
- NCT00538395
- Testing
- Adriamycin, Taxol and Cytoxan
- Volunteers
- 100 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Breast Cancer
Effect of an Amino Acids and Flavonoids Containing FSMP on Chemotherapy Toxicity, Nutritional Status and Quality of Life in Breast Cancer Patients
The goal of this clinical trial is to compare the effect of a Food for Special Medical Purposes (FSMP) mainly containing amino acids and flavonoids in combination with nutritional counseling, versus nutritional counseling alone…
- Trial name
- NCT05968677
- Testing
- FSMP, Nutritional counseling
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Flavolife Srl
HER2-positive Breast Cancer
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
This study was a phase III, multicenter, triple-blind, equivalency clinical trial to determine the therapeutic efficacy and safety between Pertuzumab® (CinnaGen Co.) compared to originator pertuzumab in HER2-positive early breast…
- Trial name
- NCT04957212
- Testing
- Trastuzumab, Pertuzumab, Carboplatin
- Where
- 44 sites in Iran
- Volunteers
- 214 people
- Sponsor
- Cinnagen
Rejuvenation, Skin Care Dermocosmetics
Consensus on Skin Care in Breast Cancer Patients
Skin toxicity is one of the most common and impactful adverse effects of breast cancer treatment, affecting patients undergoing chemotherapy, targeted therapies, endocrine therapy, and radiotherapy.
- Conditions
- Rejuvenation, Skin Care Dermocosmetics, Breast Cancer
- Trial name
- NCT07306130
- Where
- Egypt
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Venus Research Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.